Anita Johansen appointed new CEO of Probi
The Board of Directors of Probi has appointed Anita Johansen as new Chief Executive Officer of Probi effective April 1st, 2023. Anita Johansen has been employed with Probi since April 2022 as the Vice President of R&D and in the role as interim CEO since December 2022. Anita has more than 20 years of leadership experience from global consumer healthcare companies and an extensive experience with product development of nutritional and probiotic products. Prior to joining Probi she held senior leadership positions in Pfizer Consumer Healthcare, Novozymes OneHealth and USP Zdrowie. Anita holds a master’s degree in pharmacy and a PhD in pharmaceutical technology, both from the Danish University of Pharmaceutical Sciences (now University of Copenhagen) in Denmark.
“I am confident that Anita Johansen with her proven leadership skills, solid scientific and probiotic experience as well as her strong business acumen will be able to lead and support the Probi team and further strengthen the pace of innovation and manufacturing excellence and bring the company back on a profitable growth trajectory”, says Chairman of the Board Jean-Yves Parisot.
“I am honored and delighted to accept the opportunity to become Chief Executive Officer of Probi. During my previous 12 months in Probi I have become only more convinced of the fundamental strengths and the clear growth potential of our company, and I will be focused on working with the entire Probi team to deliver improved business results. I share the same passion for people and probiotics as my predecessors, and I look forward to continuing in the same spirit as the probiotic pioneers of Probi”, says Anita Johansen.
This information is information that Probi AB is obliged to make public according to the EU's Market Abuse Regulation. The information was submitted, through the care of the contact persons below, for publication on 30th March 2023 at 12.00 am CET. This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
For further information, please contact:
Jean-Yves Parisot, Chairman of the Board, Probi, Tel: +33 678 69 58 09
Henrik Lundkvist, CFO, Probi, Tel +46 46 286 89 41, E-mail: [email protected]
Om Probi
Probi® is a global Group that focuses exclusively on research, manufacturing and delivery of probiotics in dietary supplements and food. The company has expertise in managing live bacteria from research through all stages of the manufacturing process and is dedicated to making the health-promoting benefits of probiotics available to people around the world. Since the company was founded in 1991 at Lund University in Sweden, Probi has expanded its operations to more than 40 markets and holds around 400 patents worldwide. Probi had sales of SEK 618 m in 2022. Probi's shares are listed on Nasdaq Stockholm, Mid-cap, and there were around 3,700 shareholders on December 31, 2022.
